Untangling the enigma of PCOS and its distressing impacts in 12 per cent of women

ADELAIDE, Australia, Sept. 7, 2023 /PRNewswire/ — Psychological issues including anxiety, depression and negative body image are adding to the physical burden of polycystic ovary syndrome (PCOS), a hormonal disorder that affects 12 per cent of women globally.

International research has revealed that the prevalence and severity of depressive symptoms associated with PCOS are high and poorly understood with sufferers needing better emotional support and counselling.

Infertility and reduced fertility caused by PCOS are creating additional distress, particularly in societies where there is a cultural expectation of motherhood and women are held responsible for challenges to their fertility.

A major Asia Pacific fertility conference in South Australia heard today of ethnic diversity in the global prevalence of PCOS with a greater presence of the condition in women in India, Pakistan, Nepal, Afghanistan, Bangladesh, Bhutan, Iran, Sri Lanka and the Maldives.

South Asian women with PCOS are also at an increased risk of developing cardiometabolic conditions including stroke, heart attack, diabetes and liver disease.

The 2023 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Adelaide is exploring the causes and effects of PCOS with the release of new international guidelines to assist in the diagnosis and treatment of the condition. ASPIRE was a collaborating body in the development of the guidelines.

Symptoms of PCOS first appear around puberty and persist through and beyond reproductive years. They include hormonal imbalances causing dermatological issues such as excessive hair growth or hair loss from the scalp and acne, along with menstrual disorders and infertility combining to create adverse psychological outcomes.

PCOS can also lead to problems including early onset diabetes and cardiovascular disease.

Dr Duru Shah, Founder President of the PCOS Society of India, said PCOS was a complex reproductive, endocrine and metabolic disorder with puzzling causes that may include genetics, lifestyle or environmental factors. She said delays in diagnosis, particularly in girls and young women, were common in some countries including India.

“Anxiety and depression are common in PCOS sufferers especially over cosmetic issues such as obesity, hirsutism and acne, and also due to infertility associated with the condition,” Dr Shah explained.

“Body shaming is another confronting issue for these girls and women contributing to body image and self-esteem challenges.

“Obesity in adolescents persists in adulthood leading to the major health issues we see in women with PCOS.”

Dr Shah has advocated to the Ministry of Health in India to insist on an hour of exercise in schools and the provision of healthy snacks being served in school canteens.

Dr Madhuri Patil, Vice-President of the PCOS Society of India and President of the Fertility Preservation Society of India, said there were significant differences in PCOS symptoms across race or ethnic groups and geographic locations.

“We suspect genetic factors are involved in clinical manifestations of PCOS and metabolic responses between various racial and ethnic groups,” she explained. “As a result, South Asian and East Asian women may differ in metabolic function from each other and white women residing in the same region.

“The actual causes of these racial differences in PCOS outcomes remain unclear, but there is a need to highlight the benefits of healthy lifestyle strategies to prevent excess weight gain.”

The PCOS Society of India has mounted a major community awareness campaign to help girls and women learn more about PCOS and its ramifications.

The prevalence of PCOS in Chinese women has been increasing since 2010 with variations across different regions, occupations and age groups with similar upward trends observed in other countries.

The new 2023 evidence-based international guidelines for the diagnosis, assessment and treatment of PCOS were outlined at the ASPIRE Congress. The guidelines have been developed by more than 1,000 healthcare professionals including researchers, academics, multidisciplinary clinicians, patients and consumer groups.

Leader author and endocrinologist, Professor Helena Teede, Director of the National Health and Medical Research Council Centre for Research Excellence in PCOS at Monash University in Melbourne, said the guidelines addressed the misconception that PCOS was an isolated reproductive condition rather than an endocrine disorder with psychological, cardiometabolic and reproductive effects.

Professor Teede said that up to 70 per cent of women with PCOS could be diagnosed based on the presence of both menstrual irregularity and hyperandrogenism, which could include acne, female pattern hair loss or hirsutism.

“But if adults do not have one of those features, you can do an ultrasound or an anti-müllerian hormone (AMH) blood test, which is now recommended,” she explained.

Professor Teede also stressed the importance of diagnosing PCOS early, particularly in adolescence.

She said if adolescents had only one feature of PCOS they should be defined as at risk and, after the age of 20 they should be reassessed and have an ultrasound or AMH test.

In other key changes in the guidelines cardiovascular disease is now considered a core feature of PCOS with all women recommended to undergo a lipid profile at diagnosis regardless of age and BMI.

Another new recommendation includes being aware of male first-degree relatives of women with PCOS in terms of potential metabolic syndrome, type 2 diabetes and hypertension.

Professor Teede said family studies suggested a 2.3-fold increased risk for type 2 diabetes and a 1.4-fold increased risk for metabolic syndrome in fathers, and a 3.9-fold increased risk for dyslipidaemia in brothers of women with PCOS.

INTERVIEW:

ASPIRE Congress speakers are available for interview. 

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.